Philadelphia,, February 5, 2025 / Prnewswire/ -CARISMA THERAPEUTICS INC. (NASDAQ) (“CARISMA” or “COMPANY”) is a leader in a treatment that focuses on macrophages and was announced today. Steven KellyPresident and Chief Executive Officer will participate in the 35th Annual Healthcare Life Science Cunse Falence of Oppen Hymer. Tuesday, February 11th in 4:40 pm。
The audio webcast of the event can be used in the company's investor event section on the Investor Relations Web page, and is limited to the event.
About charisma
CARISMA THERAPEUTICS is a pioneering bio -pharmaceutical company in macrophage engineering to develop fibrosis, cancer, and other brief treatments. Charismas aim to provide scalable next -generation solutions to convert therapeutic paradigm by strong commitment to patient -centered innovation. Charisma is headquartered in Philadelphia, Pennsylvania. For more information, see www.carismatx.com.
Investor:
Schweta Die
(Email protection)
Media contacts:
Julia Stern
(763) 350-5223
(Email protection)
Source Carisma Therapeutics Inc.
